Secret Bull Market Starts in This Unusual Sector

"We're only at the very beginning of a new wave that could deliver 500%-plus gains in the years to come." In fact, 50 small companies related to this sector have already soared 100% or more in a recent 90-day stretch.

Click for my No. 1 investment, all free of charge, click here.

James E. Cashman, III net worth and biography

James Cashman, III Biography and Net Worth

Director of Certara

James Cashman is a veteran of the software industry for over 45 years, and serves as an advisor to numerous high tech companies. He most recently served for 20 years in the CEO and Executive Chairman roles of ANSYS, Inc. which grew from $50 million to over $1 billion in revenues over his tenure. During that span, ANSYS was one of the top 5 public technology companies in terms of total shareholder returns, while joining the S&P500 and NASDAQ-100. He has evangelized Simulation Driven Product Development which enables organizations to develop virtual prototypes, resulting in reduced testing, faster time-to-market, and better quality products. As such, he has been featured in many publications, as well as on CNBC, CNN, FBN, Bloomberg and other on-air networks.

How do I contact James E. Cashman, III?: The corporate mailing address for Mr. Cashman, III and other Certara executives is 100 OVERLOOK CENTER SUITE 101, PRINCETON NJ, 08540. Certara can also be reached via phone at 609-716-7900 and via email at [email protected]. Learn More on James E. Cashman, III's contact information.
Has James E. Cashman, III been buying or selling shares of Certara?: James E. Cashman, III has not been actively trading shares of Certara in the last ninety days. Most recently, James E. Cashman III sold 19,889 shares of the business's stock in a transaction on Wednesday, December 22nd. The shares were sold at an average price of $29.00, for a transaction totalling $576,781.00. Learn More on James E. Cashman, III's trading history.
Who are Certara's active insiders?: Certara's insider roster includes Robert Aspbury (Insider), Eran Broshy (Director), James Cashman, III (Director), Jieun Choe (Insider), Justin Edge (Insider), William Feehery (CEO), Stephen McLean (Director), Leif Pedersen (Insider), Craig Rayner (Insider), Michael Schemick (CFO), Mason Slaine (Director), Patrick Smith (Insider), Richard Traynor (SVP), and Matthew Walsh (Director). Learn More on Certara's active insiders.
Are insiders buying or selling shares of Certara?: During the last year, Certara insiders bought shares 1 times. They purchased a total of 193 shares worth more than $3,107.30. During the last year, insiders at the sold shares 7 times. They sold a total of 104,755 shares worth more than $1,776,756.55. The most recent insider tranaction occured on April, 2nd when insider Patrick F Smith sold 14,427 shares worth more than $243,094.95. Insiders at Certara own 2.6% of the company. Learn More about insider trades at Certara.
Information on this page was last updated on 4/2/2024.

James E. Cashman, III Insider Trading History at Certara

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
12/22/2021	Sell	19,889	$29.00	$576,781.00

James E. Cashman, III Buying and Selling Activity at Certara

Certara Company Overview

Certara, Inc., together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics. The company provides Simcyp Simulator, a mechanistic biosimulation platform mechanistic biosimulation investigational new drug and translational stages; Simcyp Biopharmaceutics, used to identify and refine drug formulations; and Simcyp Secondary Intelligence which integrates toxicology with quantitative analysis of networks of molecular and functional biological changes to identify drug toxicity and adverse drug reactions. In addition, it offers Phoenix WinNonlin, a platform for non-compartmental analysis, pharmacokinetic/pharmacodynamic, and toxicokinetic; phoenix hosted, that provides a secured and validated certara amazon web services workspace; Phoenix NLME, a population modeling and simulation software for nonlinear mixed effects models; and pirana modeling workbench. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange, used to define data standards and specifications; and Metadata Repository, to enable study design using controlled and standardized data. It serves life sciences companies, biopharmaceutical companies, research organizations, academic institutions, and global regulators, as well as animal health, crop science, bio science, medical devices, and public sector industries. Certara Inc. was founded in 2008 and is headquartered in Princeton, New Jersey.

Today's Range

Now: $15.93

$15.83

$16.34

50 Day Range

MA: $17.85

$16.21

$19.45

2 Week Range

Now: $15.93

$11.81

$24.96

Volume

610,371 shs

Average Volume

539,909 shs

Market Capitalization

$2.55 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.63